<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30810669</article-id><article-id pub-id-type="pmc">6385828</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2018-0171</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Clinical Significance of Cys-C and hs-CRP in Coronary Heart Disease
Patients Undergoing Percutaneous Coronary Intervention</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5202-9580</contrib-id><name><surname>Tan</surname><given-names>Zheng</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>Bachelor</role></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Yi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Geng</surname><given-names>Xuebin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>Bachelor</role></contrib><aff id="aff1">
<label>1</label> Second Department of Cardiovasology, Tangshan Gongren Hospital,
Hebei, China. </aff></contrib-group><author-notes><corresp id="c1">Correspondence Address: <bold>Zheng Tan</bold>,
http://orcid.org/0000-0002-5202-9580, Second Department of Cardiovasology,
Tangshan Gongren Hospital, 27 Wenhua Road - Tangshan, Hebei, China - Zip Code:
063000. E-mail: <email>zhentants11@163.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jan-Feb</season><year>2019</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2019</year></pub-date><volume>34</volume><issue>1</issue><fpage>17</fpage><lpage>21</lpage><history><date date-type="received"><day>11</day><month>6</month><year>2018</year></date><date date-type="accepted"><day>31</day><month>7</month><year>2018</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>To investigate the clinical significance of serum cystatin C (Cys-C) and
high-sensitivity C-reactive protein (hs-CRP) in coronary heart disease (CHD)
patients undergoing percutaneous coronary intervention (PCI).</p></sec><sec><title>Methods</title><p>One hundred and twenty-eight CHD patients were divided into drug treatment
(56 cases) and PCI treatment (72 cases) groups, receiving conventional drug
treatment and PCI plus conventional drug treatment, respectively. At
admission time and 4 weeks after treatment, the left ventricular ejection
fraction (LVEF), left ventricular end diastolic diameter, and left
ventricular end systolic diameter were measured. At admission time and 24h,
72h, 1 week, and 4 weeks after treatment, the serum levels of Cys-C and
hs-CRP were determined.</p></sec><sec><title>Results</title><p>After 4 weeks of treatment, LVEF in the PCI treatment group was significantly
higher than that before treatment (<italic>P</italic>&#x0003c;0.01) and it was
significantly higher than in the drug treatment group at the same time
(<italic>P</italic>&#x0003c;0.01). Cys-C and hs-CRP level in the PCI
treatment group were significantly higher than in the drug treatment group
72h and 1 week after treatment (<italic>P</italic>&#x0003c;0.05 or
<italic>P</italic>&#x0003c;0.01), respectively, but they were significantly
lower than in the drug treatment group 4 weeks after treatment
(<italic>P</italic>&#x0003c;0.01). There were obvious interaction effects
between grouping factor and time factor in Cys-C (F=3.62,
<italic>P</italic>&#x0003c;0.05) and hs-CRP (F=17.85,
<italic>P</italic>&#x0003c;0.01).</p></sec><sec><title>Conclusion</title><p>Serum levels of Cys-C and hs-CRP are closely related to the heart function in
CHD patients undergoing PCI, and they may be used for predicting the outcome
of PCI.</p></sec></abstract><kwd-group><kwd>Coronary Disease</kwd><kwd>Percutaneous Coronary Intervention</kwd><kwd>Cystatin C</kwd><kwd>C-Reactive Protein</kwd></kwd-group></article-meta></front><body><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">BMI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Body mass index</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">BUN</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Blood urea nitrogen</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CAG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary
angiography</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CHD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary heart
disease</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">Cys-C</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cystatin C</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">hs-CRP</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= High-sensitivity
C-reactive protein</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ISR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= In-stent restenosis</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LVEDD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricular end
diastolic diameter</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LVEF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricular
ejection fraction</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LVESD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricular end
systolic diameter</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PCI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Percutaneous coronary
intervention</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">Scr</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Serum creatinine</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Coronary heart disease (CHD) is the myocardial functional or organic lesion due to
coronary artery stenosis or occlusion, or shortage of blood and oxygen
supply<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. It is one of the common causes of death due to
cardiovascular diseases<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>. The formation of CHD is result of the interaction
among multiple risk factors, in which the vascular endothelial inflammatory response
caused by coronary atherosclerosis is an important mechanism<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>. Percutaneous coronary
intervention (PCI) is one of the most important methods for the treatment of severe
CHD, but in-stent restenosis (ISR) will affect the long-term curative
effect<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>, and doctors and patients are very concerned about this
problem. Selective coronary angiography (CAG) is the gold standard exam for
diagnosis of ISR after PCI<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>. However, CAG is an invasive examination method and
it is not conducive to the popularization of follow-up after PCI and timely finding
ISR<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>.
Seeking blood biochemical indicators for predicting ISR in clinics has become a
focus in academic and research fields.</p><p>It is reported that some indicators in serum, in addition to the traditional risk
factors (<italic>e.g.</italic>, age, gender, blood pressure, blood lipids, etc.),
can also be used as independent risk factors for CHD and that they are closely
related to the incidence of cardiovascular events<sup>[<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r8" ref-type="bibr">8</xref>]</sup>. High-sensitivity
C-reactive protein (hs-CRP) is one of the inflammatory markers, which is synthesized
by the liver. It can be used for predicting the risk of cardiovascular
diseases<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>. Cystatin C (Cys-C) is a low-molecular-weight (13
kDa) protein that is a member of the cysteine protease family and is produced by all
nucleated cells. Cys-C is involved in a variety of inflammatory reactions. It is a
sensitive indicator of the degree of renal arteriosclerosis<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup> and it is also used as
an emerging biomarker in cardiovascular disease<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>. This study aimed to
investigate the clinical significance of Cys-C and hs-CRP in CHD patients undergoing
PCI to provide a reference for the application of Cys-C and hs-CRP to monitor PCI
treatment in CHD patients.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Patients</title><p>One hundred and twenty-eight patients diagnosed with unstable angina pectoris of
CHD by CAG from September 2015 to March 2016 in our hospital were enrolled in
this study. There were 68 males and 60 females. The patients' ages were 51-78
years (59.8&#x000b1;6.4 years). According to the treatment method, the patients
were divided into PCI treatment group (72 cases) and drug treatment group (56
cases). The following cases were excluded: i) patients with severe disease in
respiratory system, blood system, or immune system; ii) patients with infectious
disease, malignant tumor, or severe liver or kidney dysfunction; iii) patients
with severe cardiac insufficiency (left ventricular ejection fraction [LVEF]
&#x0003c;35%) or heart valve disease; iv) patients with unclear language expression
or mental disorders. This study was approved by the Ethics Committee of
GRYY-LL-2015-28. Written informed consent was obtained from patients or their
families.</p></sec><sec><title>Treatment</title><p>After admission, the drug treatment group received conservative treatment using
statins, nitrates, beta blockers, anti-platelet drugs, angiotensin-converting
enzyme inhibitors, and other conventional drugs. The PCI treatment group was
given PCI treatment plus conventional drug treatment. There was no significant
difference in diuretics use between the two groups. PCI was performed according
to the "Guidelines for PCI in China" promulgated by the Chinese Medical
Association of Cardiovascular Disease in 2012<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>.</p></sec><sec><title>Detection of Heart Function Indexes</title><p>At the admission time and 4 weeks after treatment, echocardiography was performed
using the Vivid 7 Cardiac ultrasonic examination instrument (GE Healthcare, WI,
USA), and the heart function indexes including LVEF, left ventricular end
diastolic diameter (LVEDD), and left ventricular end systolic diameter (LVESD)
were measured.</p></sec><sec><title>Detection of Cys-C and hs-CRP</title><p>At the admission time and 24h, 72h, 1 week, and 4 weeks after treatment, 5 ml of
fasting venous blood were taken from the patients. After centrifugation at 2000
r/m (4&#x000ba;C) for 5 min, the serum was obtained, and it was stored at -80&#x000ba;C for use.
Cys-C level was measured by particle-enhanced nephelometric immunoassay using
BA800 automatic biochemical analyzer (Beijing Leadman Company, Beijing, China)
and Cys-C kits (Shanghai Sangon Biological Engineering Technology and Service
Co., Ltd., Shanghai, China). The level of hs-CRP was measured by
immunofluorescence assay using i-CHROMA<sup>TM</sup> immune fluorescence
analyzer (Boditech Med Inc., Seoul, South Korea) and hs-CRP kits (Shanghai
Sangon Biological Engineering Technology and Service Co., Ltd., Shanghai,
China).</p></sec><sec><title>Statistical Analysis</title><p>All statistical analyses were carried out using SPSS17.0 software (SPSS Inc.,
Chicago, IL, USA). Data were presented as mean &#x000b1; standard deviation.
Comparisons of enumeration data and measurement data were performed with
&#x003c7;<sup>2</sup> test and t-test, respectively. Before and after
treatment data were compared by paired-sample t-test. <italic>P</italic>&#x0003c;0.05
was considered as statistically significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Patients' General Information</title><p>The general information of the patients in the two groups is shown in <xref rid="t1" ref-type="table">Table 1</xref>. There is no significant difference
of age, body mass index (BMI), serum creatinine (Scr) and blood urea nitrogen
(BUN), smoking, CHD family history, hypertension prevalence rate, hyperlipidemia
prevalence, or diabetes prevalence rate between the two groups
(<italic>P</italic>&#x0003e;0.05).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>General information of patients in the two groups.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">Age (years)</th><th align="center" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</th><th align="center" rowspan="1" colspan="1">Scr (&#x000b5;mol /L)</th><th align="center" rowspan="1" colspan="1">BUN (mmol /L)</th><th align="center" rowspan="1" colspan="1">Smoking [n (%)]</th><th align="center" rowspan="1" colspan="1">CHD family history [n (%)]</th><th align="center" rowspan="1" colspan="1">Hypertension [n (%)]</th><th align="center" rowspan="1" colspan="1">Hyperlipidemia [n (%)]</th><th align="center" rowspan="1" colspan="1">Diabetes [n (%)]</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Drug treatment (n=56)</td><td align="center" rowspan="1" colspan="1">58.2&#x000b1;5.2</td><td align="center" rowspan="1" colspan="1">22.2&#x000b1;2.6</td><td align="center" rowspan="1" colspan="1">55.6&#x000b1;8.4</td><td align="center" rowspan="1" colspan="1">5.9&#x000b1;1.1</td><td align="center" rowspan="1" colspan="1">13 (23.2)</td><td align="center" rowspan="1" colspan="1">12 (21.4)</td><td align="center" rowspan="1" colspan="1">14 (25.0)</td><td align="center" rowspan="1" colspan="1">12 (21.4)</td><td align="center" rowspan="1" colspan="1">10 (17.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">PCI treatment (n=72)</td><td align="center" rowspan="1" colspan="1">60.9&#x000b1;5.3</td><td align="center" rowspan="1" colspan="1">22.4&#x000b1;2.2</td><td align="center" rowspan="1" colspan="1">57.2&#x000b1;9.3</td><td align="center" rowspan="1" colspan="1">5.8&#x000b1;1.5</td><td align="center" rowspan="1" colspan="1">18 (25.0)</td><td align="center" rowspan="1" colspan="1">16 (22.2)</td><td align="center" rowspan="1" colspan="1">17 (23.1)</td><td align="center" rowspan="1" colspan="1">15 (20.8)</td><td align="center" rowspan="1" colspan="1">13 (18.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">t/x<sup>2</sup></td><td align="center" rowspan="1" colspan="1">0.473</td><td align="center" rowspan="1" colspan="1">0.725</td><td align="center" rowspan="1" colspan="1">0.741</td><td align="center" rowspan="1" colspan="1">0.570</td><td align="center" rowspan="1" colspan="1">0.831</td><td align="center" rowspan="1" colspan="1">0.846</td><td align="center" rowspan="1" colspan="1">0.422</td><td align="center" rowspan="1" colspan="1">1.213</td><td align="center" rowspan="1" colspan="1">0.105</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>P</italic></td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>BMI=body mass index; BUN=blood urea nitrogen; CHD=coronary heart
disease; PCI=percutaneous coronary intervention; Scr=serum
creatinine</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Comparison of Heart Function Indexes Before and After Treatment in the Two
Groups</title><p>In the drug treatment group, LVEF, LVEDD, and LVESD before treatment were
52.12&#x000b1;6.18%, 48.95&#x000b1;6.78 mm, and 38.06&#x000b1;5.76 mm,
respectively, and 1 month after treatment those were 58.46&#x000b1;7.84%,
49.21&#x000b1;5.46 mm, and 37.46&#x000b1;5.13 mm, respectively.</p><p>In the PCI treatment group, LVEF, LVEDD, and LVESD before treatment were
53.35&#x000b1;5 and 49.78&#x000b1;6.03 mm, and 37.53&#x000b1;4.97 mm respectively,
and 1 month after treatment those were 69.60&#x000b1;8.21%, 51.03&#x000b1;5.24 mm,
and 37.02&#x000b1;5.04 mm, respectively.</p><p>Before treatment, there was no significant difference between each index of the
two groups (<italic>P</italic>&#x0003e;0.05). After treatment, LVEF in the PCI
treatment group was significantly higher than that before treatment
(<italic>P</italic>&#x0003c;0.01) and it was significantly higher than in the
drug treatment group at the same time (<italic>P</italic>&#x0003c;0.01). LVEDD and
LVESD had no significant difference before and after treatment in each group,
with no significant difference between the two groups after treatment
(<italic>P</italic>&#x0003e;0.05) (<xref rid="t2" ref-type="table">Table
2</xref>).</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Comparison of heart function indexes before and after treatment in the
two groups.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">Heart function index</th><th align="center" rowspan="1" colspan="1">Before treatment</th><th align="center" rowspan="1" colspan="1">4 weeks after treatment</th></tr></thead><tbody><tr><td align="left" rowspan="3" colspan="1">Drug treatment</td><td align="center" rowspan="1" colspan="1">LVEF (%)</td><td align="center" rowspan="1" colspan="1">52.12&#x000b1;6.18</td><td align="center" rowspan="1" colspan="1">58.46&#x000b1;7.84</td></tr><tr><td align="center" rowspan="1" colspan="1">LVEDD (mm)</td><td align="center" rowspan="1" colspan="1">48.95&#x000b1;6.78</td><td align="center" rowspan="1" colspan="1">49.21&#x000b1;5.46</td></tr><tr><td align="center" rowspan="1" colspan="1">LVESD (mm)</td><td align="center" rowspan="1" colspan="1">38.06&#x000b1;5.76</td><td align="center" rowspan="1" colspan="1">37.46&#x000b1;5.13</td></tr><tr><td align="left" rowspan="3" colspan="1">PCI treatment</td><td align="center" rowspan="1" colspan="1">LVEF (%)</td><td align="center" rowspan="1" colspan="1">53.35&#x000b1;5.46</td><td align="center" rowspan="1" colspan="1">69.60&#x000b1;8.21<sup><xref ref-type="table-fn" rid="TFN2">a</xref><xref ref-type="table-fn" rid="TFN3">b</xref></sup></td></tr><tr><td align="center" rowspan="1" colspan="1">LVEDD (mm)</td><td align="center" rowspan="1" colspan="1">49.78&#x000b1;6.03</td><td align="center" rowspan="1" colspan="1">51.03&#x000b1;5.24</td></tr><tr><td align="center" rowspan="1" colspan="1">LVESD (mm)</td><td align="center" rowspan="1" colspan="1">37.53&#x000b1;4.97</td><td align="center" rowspan="1" colspan="1">37.02&#x000b1;5.04</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><label>a</label><p><italic>P</italic>&#x0003c;0.01 compared with before treatment;</p></fn><fn id="TFN3"><label>b</label><p><italic>P</italic>&#x0003c;0.01 compared with drug treatment group.</p></fn><fn id="TFN4"><p>LVEDD=left ventricular end diastolic diameter; LVEF=left ventricular
ejection fraction; LVESD=left ventricular end systolic diameter;
PCI=percutaneous coronary intervention</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Comparison of Cys-C Level Before and After Treatment in the Two
Groups</title><p>In the drug treatment group, Cys-C level before treatment and 24h, 72h, 1 week,
and 4 weeks after treatment was 1.25&#x000b1;0.31, 1.29&#x000b1;0.34,
1.38&#x000b1;0.33, 1.26&#x000b1;0.34, and 1.24&#x000b1;0.32 mg/L, respectively, and
in the PCI treatment group, Cys-C level was 1.32&#x000b1;0.35, 1.43&#x000b1;0.46,
1.58&#x000b1;0.51, 1.41&#x000b1;0.42, and 1.08&#x000b1;0.29 mg/L, respectively.
There was no significant difference of Cys-C level between the two groups before
treatment and 24h after treatment (<italic>P</italic>&#x0003e;0.05). Cys-C level in
the PCI treatment group was significantly higher than in the drug treatment
group 72h and 1 week after treatment (<italic>P</italic>&#x0003c;0.05 or
<italic>P</italic>&#x0003c;0.01), respectively, but it was significantly lower
than in the drug treatment group 4 weeks after treatment
(<italic>P</italic>&#x0003c;0.01). The difference was also significant among
different time points in each group (<italic>P</italic>&#x0003c;0.05 or
<italic>P</italic>&#x0003c;0.01). Cys-C level in the PCI treatment group reached
the peak at 72h after treatment and then decreased gradually. There was an
obvious interaction effect between grouping factor and time factor (F=3.62,
<italic>P</italic>&#x0003c;0.05) (<xref rid="t3" ref-type="table">Table
3</xref>).</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Comparison of Cys-C level before and after treatment in the two groups
(mg/L).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Group</th><th align="center" rowspan="2" colspan="1">n</th><th align="center" rowspan="2" colspan="1">Before treatment</th><th align="center" colspan="4" rowspan="1">After treatment</th><th align="center" rowspan="2" colspan="1">F</th><th align="center" rowspan="2" colspan="1"><italic>P</italic></th></tr><tr><th align="center" rowspan="1" colspan="1">24 h</th><th align="center" rowspan="1" colspan="1">72 h</th><th align="center" rowspan="1" colspan="1">1 week</th><th align="center" rowspan="1" colspan="1">4 weeks</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Drug treatment</td><td align="center" rowspan="1" colspan="1">56</td><td align="center" rowspan="1" colspan="1">1.25&#x000b1;0.31</td><td align="center" rowspan="1" colspan="1">1.29&#x000b1;0.34</td><td align="center" rowspan="1" colspan="1">1.38&#x000b1;0.33</td><td align="center" rowspan="1" colspan="1">1.26&#x000b1;0.34</td><td align="center" rowspan="1" colspan="1">1.24&#x000b1;0.32</td><td align="center" rowspan="1" colspan="1">3.18</td><td align="center" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">PCI treatment</td><td align="center" rowspan="1" colspan="1">72</td><td align="center" rowspan="1" colspan="1">1.32&#x000b1;0.35</td><td align="center" rowspan="1" colspan="1">1.43&#x000b1;0.46</td><td align="center" rowspan="1" colspan="1">1.58&#x000b1;0.51</td><td align="center" rowspan="1" colspan="1">1.41&#x000b1;0.42</td><td align="center" rowspan="1" colspan="1">1.08&#x000b1;0.29</td><td align="center" rowspan="1" colspan="1">8.65</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">T</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">1.18</td><td align="center" rowspan="1" colspan="1">1.91</td><td align="center" rowspan="1" colspan="1">2.01</td><td align="center" rowspan="1" colspan="1">2.17</td><td align="center" rowspan="1" colspan="1">2.96</td><td align="center" rowspan="1" colspan="1">3.62</td><td align="center" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>P</italic></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">0.24</td><td align="center" rowspan="1" colspan="1">0.06</td><td align="center" rowspan="1" colspan="1">0.04</td><td align="center" rowspan="1" colspan="1">0.03</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TFN5"><p>Cys-C=cystatin C; PCI=percutaneous coronary intervention</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Comparison of hs-CRP Level Before and After Treatment in the Two
Groups</title><p>As shown in <xref rid="t4" ref-type="table">Table 4</xref>, in the drug treatment
group, hs-CRP level before treatment and 24h, 72h, 1 week, and 4 weeks after
treatment was 3.69&#x000b1;1.09, 4.05&#x000b1;2.01, 9.65&#x000b1;4.12,
7.04&#x000b1;3.24, and 3.85&#x000b1;1.02 mg/L, respectively, and in the PCI
treatment group, hs-CRP level was 3.72&#x000b1;1.12, 4.13&#x000b1;1.98,
14.10&#x000b1;5.97, 9.76&#x000b1;5.41, and 2.35&#x000b1;0.97 mg/L, respectively.
There was a significant difference among different time points in each group
(<italic>P</italic>&#x0003c;0.05 or <italic>P</italic>&#x0003c;0.01). There was no
significant difference of hs-CRP level between the two groups before treatment
and 24h after treatment (<italic>P</italic>&#x0003e;0.05). In the PCI treatment
group, hs-CRP level was significantly higher than in the drug treatment group
72h and 1 week after treatment (<italic>P</italic>&#x0003c;0.05 or
<italic>P</italic>&#x0003c;0.01), respectively, but it was significantly lower than
in the drug treatment group 4 weeks after treatment
(<italic>P</italic>&#x0003c;0.01). In the PCI treatment group, hs-CRP level reached
the peak at 72h after treatment and then decreased gradually. There was also an
obvious interaction effect between grouping factor and time factor (F=17.85,
<italic>P</italic>&#x0003c;0.01) (<xref rid="t4" ref-type="table">Table
4</xref>).</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Comparison of hs-CRP level before and after treatment in the two groups
(mg/L).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Group</th><th align="center" rowspan="2" colspan="1">n</th><th align="center" rowspan="2" colspan="1">Before treatment</th><th align="center" colspan="4" rowspan="1">After treatment</th><th align="center" rowspan="2" colspan="1">F</th><th align="center" rowspan="2" colspan="1"><italic>P</italic></th></tr><tr><th align="center" rowspan="1" colspan="1">24 h</th><th align="center" rowspan="1" colspan="1">72 h</th><th align="center" rowspan="1" colspan="1">1 week</th><th align="center" rowspan="1" colspan="1">4 weeks</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Drug treatment</td><td align="center" rowspan="1" colspan="1">56</td><td align="center" rowspan="1" colspan="1">3.69&#x000b1;1.09</td><td align="center" rowspan="1" colspan="1">4.05&#x000b1;2.01</td><td align="center" rowspan="1" colspan="1">9.65&#x000b1;4.12</td><td align="center" rowspan="1" colspan="1">7.04&#x000b1;3.24</td><td align="center" rowspan="1" colspan="1">3.85&#x000b1;1.02</td><td align="center" rowspan="1" colspan="1">20.60</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">PCI treatment</td><td align="center" rowspan="1" colspan="1">72</td><td align="center" rowspan="1" colspan="1">3.72&#x000b1;1.12</td><td align="center" rowspan="1" colspan="1">4.13&#x000b1;1.98</td><td align="center" rowspan="1" colspan="1">14.10&#x000b1;5.97</td><td align="center" rowspan="1" colspan="1">9.76&#x000b1;5.41</td><td align="center" rowspan="1" colspan="1">2.35&#x000b1;0.97</td><td align="center" rowspan="1" colspan="1">34.56</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">T</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">0.15</td><td align="center" rowspan="1" colspan="1">0.23</td><td align="center" rowspan="1" colspan="1">4.76</td><td align="center" rowspan="1" colspan="1">3.33</td><td align="center" rowspan="1" colspan="1">8.49</td><td align="center" rowspan="1" colspan="1">17.85</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>P</italic></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">0.88</td><td align="center" rowspan="1" colspan="1">0.82</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TFN6"><p>hs-CRP=high-sensitivity C-reactive protein; PCI=percutaneous coronary
intervention</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>PCI is a non-surgical method used to treat narrowed coronary arteries that supply the
heart muscle with blood<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>. PCI has been clinically applied for almost 30
years and has become one of the main treatments for CHD<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>. PCI with coronary
stent implantation has been demonstrated to consistently reduce the symptoms of
coronary artery disease and decrease cardiac ischemia<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>. In this study, PCI
plus conventional drug treatment was performed in CHD patients. Results showed that,
after 4 weeks of treatment, LVEF in the PCI treatment group was significantly higher
than that before treatment (<italic>P</italic>&#x0003c;0.01) and it was significantly
higher than in the drug treatment group at the same time
(<italic>P</italic>&#x0003c;0.01). This indicates that PCI can significantly elevate LVEF
in CHD patients, improving the heart functions.</p><p>Cys-C is a low-molecular-weight secretory protein of the human
body<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>. As an endogenous cysteine protease, it is an ideal
indicator to reflect the glomerular filtration rate<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>. It is reported that
there is a certain degree of correlation between the degrees of renal
arteriosclerosis and coronary artery atherosclerosis<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>. Cys-C participates in
the remodeling of extracellular matrix in CHD. In coronary atherosclerosis, the
balance of Cys-C and its inhibitor is destroyed, leading to increased degradation in
the internal elastic membrane of coronary artery and extracellular matrix. So, many
monocytes and macrophages enter the intima, leading to coronary artery plaque
formation<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>. Results of this study show that there was a
significant difference of Cys-C level among different time points in each group
(<italic>P</italic>&#x0003c;0.05 or <italic>P</italic>&#x0003c;0.01). Cys-C level in the
PCI treatment group reached the peak at 72h after treatment and then decreased
gradually. Cys-C level in the PCI treatment group was significantly higher than the
in the drug treatment group 72h and 1 week after treatment
(<italic>P</italic>&#x0003c;0.05 or <italic>P</italic>&#x0003c;0.01), respectively, but it was
significantly lower than in the drug treatment group 4 weeks after treatment
(<italic>P</italic>&#x0003c;0.01). The reason may be that the PCI results in the
acute injury of the coronary artery and the application of contrast agent cause
renal dysfunction. After 4 weeks, the renal function is completely recovered, so the
Cys-C level is significantly decreased. This is similar to the results of previous
clinical reports<sup>[<xref rid="r20" ref-type="bibr">20</xref>,<xref rid="r21" ref-type="bibr">21</xref>]</sup>.</p><p>hs-CRP is a non-specific inflammatory marker, which mainly reflects the human body
injury, inflammation, and infection<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>. In recent years, with the application of
ultra-sensitive detection technology, the trace amount of hs-CRP can be easily
detected<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>. It is reported that hs-CRP mediated inflammation
plays a key role in the occurrence and development of coronary atherosclerosis. The
level of hs-CRP increases in the early stage of coronary artery lesion and a large
number of hs-CRP can be detected in the early stage of coronary atherosclerotic
plaque<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>. Results of this study showed that there was a
significant difference of hs-CRP level among different time points in each group
(<italic>P</italic>&#x0003c;0.05 or <italic>P</italic>&#x0003c;0.01). In the PCI treatment
group, hs-CRP level reached the peak at 72h after treatment and then decreased
gradually. In the PCI treatment group, hs-CRP level was significantly higher than
the in the drug treatment group 72h and 1 week after treatment
(<italic>P</italic>&#x0003c;0.05 or <italic>P</italic>&#x0003c;0.01), respectively, but it was
significantly lower than in the drug treatment group 4 weeks after treatment
(<italic>P</italic>&#x0003c;0.01). The reasons may be the PCI results in the acute
injury of the coronary artery, leading to acute elevation of hs-CRP in the short
term. After 4 weeks of operative recovery and coronary revascularization, the
coronary endothelial function is more significantly restored. Therefore, the
varieties of inflammatory factors are inhibited, and the level of hs-CRP also
decreases significantly.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>In conclusion, the serum levels of Cys-C and hs-CRP are closely related to the heart
function in CHD patients undergoing PCI and they may be used for predicting the
outcome of PCI. This study still has some limitations. Firstly, the sample size of
patients is relatively small, which may affect the persuasiveness of the results;
secondly, troponin and creatine kinase are important factors for evaluating the
outcome of CHD, however, they were not investigated in this study. These are the
inadequacies of this study. In our next studies, the sample size should be further
increased and other factors, including troponin and creatine kinase, should be
investigated in order to obtain more satisfactory outcomes.</p><table-wrap id="t6" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">ZT</td><td align="left" valign="top" rowspan="1" colspan="1">Agreement to be accountable for all
aspects of the work in ensuring that questions related to the
accuracy or integrity of any part of the work are appropriately
investigated and resolved; final approval of the version to be
published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LL</td><td align="left" valign="top" rowspan="1" colspan="1">Agreement to be accountable for all
aspects of the work in ensuring that questions related to the
accuracy or integrity of any part of the work are appropriately
investigated and resolved; final approval of the version to be
published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">YM</td><td align="left" valign="top" rowspan="1" colspan="1">Agreement to be accountable for all
aspects of the work in ensuring that questions related to the
accuracy or integrity of any part of the work are appropriately
investigated and resolved; final approval of the version to be
published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">XG</td><td align="left" valign="top" rowspan="1" colspan="1">Agreement to be accountable for all
aspects of the work in ensuring that questions related to the
accuracy or integrity of any part of the work are appropriately
investigated and resolved; final approval of the version to be
published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at the Second Department of Cardiovasology, Tangshan
Gongren Hospital, Hebei, China.</p></fn><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walfridsson</surname><given-names>H</given-names></name><name><surname>Lund</surname><given-names>N</given-names></name></person-group><article-title>Tissue oxygen pressure in normal myocardium and across the border
zone during coronary artery occlusion in the pig. Effects of different
arterial oxygen pressures</article-title><source>Basic Res Cardiol</source><year>1990</year><volume>85</volume><issue>5</issue><fpage>467</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">2275702</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castelli</surname><given-names>WP</given-names></name></person-group><article-title>Epidemiology of coronary heart disease: the Framingham
study</article-title><source>Am J Med</source><year>1984</year><volume>76</volume><issue>2A</issue><fpage>4</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">6702862</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrivastava</surname><given-names>AK</given-names></name><name><surname>Singh</surname><given-names>HV</given-names></name><name><surname>Raizada</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>SK</given-names></name></person-group><article-title>C-reactive protein, inflammation and coronary heart
disease</article-title><source>Egypt Heart J</source><year>2015</year><volume>67</volume><issue>2</issue><fpage>89</fpage><lpage>97</lpage></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Throndson</surname><given-names>K</given-names></name><name><surname>Sawatzky</surname><given-names>JA</given-names></name></person-group><article-title>Angina following percutaneous coronary intervention: in-stent
restenosis</article-title><source>Can J Cardiovasc Nurs</source><year>2009</year><volume>19</volume><issue>3</issue><fpage>16</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">19694113</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tonino</surname><given-names>PA</given-names></name><name><surname>De Bruyne</surname><given-names>B</given-names></name><name><surname>Pijls</surname><given-names>NH</given-names></name><name><surname>Siebert</surname><given-names>U</given-names></name><name><surname>Ikeno</surname><given-names>F</given-names></name><name><surname>van't Veer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Fractional flow reserve versus angiography for guiding
percutaneous coronary intervention</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><issue>3</issue><fpage>213</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">19144937</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pilz</surname><given-names>G</given-names></name><name><surname>Bernhardt</surname><given-names>P</given-names></name><name><surname>Klos</surname><given-names>M</given-names></name><name><surname>Ali</surname><given-names>E</given-names></name><name><surname>Wild</surname><given-names>M</given-names></name><name><surname>H&#x000f6;fling</surname><given-names>B</given-names></name></person-group><article-title>Clinical implication of adenosine-stress cardiac magnetic
resonance imaging as potential gatekeeper prior to invasive examination in
patients with AHA/ACC class II indication for coronary
angiography</article-title><source>Clin Res Cardiol</source><year>2006</year><volume>95</volume><issue>10</issue><fpage>531</fpage><lpage>538</lpage><pub-id pub-id-type="pmid">16897145</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Chuang</surname><given-names>SY</given-names></name><name><surname>Fang</surname><given-names>CC</given-names></name><name><surname>Huang</surname><given-names>LC</given-names></name><name><surname>Hsieh</surname><given-names>IC</given-names></name><name><surname>Pan</surname><given-names>WH</given-names></name><etal/></person-group><article-title>Gender difference in statin intervention on blood lipid control
among patients with coronary heart disease</article-title><source>Int J Gerontol</source><year>2013</year><volume>7</volume><issue>2</issue><fpage>116</fpage><lpage>121</lpage></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>R</given-names></name><name><surname>Peto</surname><given-names>R</given-names></name><name><surname>MacMahon</surname><given-names>S</given-names></name><name><surname>Hebert</surname><given-names>P</given-names></name><name><surname>Fiebach</surname><given-names>NH</given-names></name><name><surname>Eberlein</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Blood pressure, stroke, and coronary heart disease. Part 2,
Short-term reductions in blood pressure: overview of randomised drug trials
in their epidemiological context</article-title><source>Lancet</source><year>1990</year><volume>335</volume><issue>8693</issue><fpage>827</fpage><lpage>838</lpage><pub-id pub-id-type="pmid">1969567</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jialal</surname><given-names>I</given-names></name><name><surname>Devaraj</surname><given-names>S</given-names></name></person-group><article-title>Inflammation and atherosclerosis: the value of the
high-sensitivity C-reactive protein assay as a risk marker</article-title><source>Am J Clin Pathol</source><year>2001</year><volume>116</volume><issue>Suppl</issue><fpage>S108</fpage><lpage>S115</lpage><pub-id pub-id-type="pmid">11993695</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaffanello</surname><given-names>M</given-names></name><name><surname>Franchini</surname><given-names>M</given-names></name><name><surname>Fanos</surname><given-names>V</given-names></name></person-group><article-title>Is serum cystatin-C a suitable marker of renal function in
children?</article-title><source>Ann Clin Lab Sci</source><year>2007</year><volume>37</volume><issue>3</issue><fpage>233</fpage><lpage>240</lpage><pub-id pub-id-type="pmid">17709686</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angelidis</surname><given-names>C</given-names></name><name><surname>Deftereos</surname><given-names>S</given-names></name><name><surname>Giannopoulos</surname><given-names>G</given-names></name><name><surname>Anatoliotakis</surname><given-names>N</given-names></name><name><surname>Bouras</surname><given-names>G</given-names></name><name><surname>Hatzis</surname><given-names>G</given-names></name><etal/></person-group><article-title>Cystatin C: an emerging biomarker in cardiovascular
disease</article-title><source>Curr Top Med Chem</source><year>2013</year><volume>13</volume><issue>2</issue><fpage>164</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">23470076</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Section of Interventional Cardiology, Chinese Society of Cardiology
of Chinese Medical Association</collab><collab>Editorial Board of Chinese Journal of Cardiology</collab></person-group><article-title>Chinese guideline for percutaneous coronary intervention (pocket
guideline)</article-title><source>Zhonghua Xin Xue Guan Bing Za Zhi</source><year>2012</year><volume>40</volume><issue>4</issue><fpage>271</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">22801302</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aradi</surname><given-names>D</given-names></name><name><surname>Kom&#x000f3;csi</surname><given-names>A</given-names></name><name><surname>Price</surname><given-names>MJ</given-names></name><name><surname>Cuisset</surname><given-names>T</given-names></name><name><surname>Ari</surname><given-names>H</given-names></name><name><surname>Hazarbasanov</surname><given-names>D</given-names></name><etal/></person-group><article-title>Efficacy and safety of intensified antiplatelet therapy on the
basis of platelet reactivity testing in patients after percutaneous coronary
intervention: systematic review and meta-analysis</article-title><source>Int J Cardiol</source><year>2013</year><volume>167</volume><issue>5</issue><fpage>2140</fpage><lpage>2148</lpage><pub-id pub-id-type="pmid">22704866</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meryon</surname><given-names>I</given-names></name><name><surname>Patel</surname><given-names>N</given-names></name><name><surname>Millane</surname><given-names>T</given-names></name><name><surname>Varma</surname><given-names>C</given-names></name></person-group><article-title>Normal coronary angiography and primary percutaneous coronary
intervention for ST elevation myocardial infarction: a literature review and
audit findings</article-title><source>Int J Clin Pract</source><year>2010</year><volume>64</volume><issue>9</issue><fpage>1245</fpage><lpage>1251</lpage><pub-id pub-id-type="pmid">20653800</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mercado</surname><given-names>N</given-names></name><name><surname>Serruys</surname><given-names>PW</given-names></name></person-group><article-title>A meta-analytical approach for the treatment of in-stent
restenosis</article-title><source>Eur Heart J</source><year>2003</year><volume>24</volume><issue>3</issue><fpage>217</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">12590898</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Xin</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Serum cystatin C concentration as an independent marker for
hypertensive left ventricular hypertrophy</article-title><source>J Geriatr Cardiol</source><year>2013</year><volume>10</volume><issue>3</issue><fpage>286</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">24133518</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>LA</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name><name><surname>Schmid</surname><given-names>CH</given-names></name><name><surname>Feldman</surname><given-names>HI</given-names></name><name><surname>Froissart</surname><given-names>M</given-names></name><name><surname>Kusek</surname><given-names>J</given-names></name><etal/></person-group><article-title>Estimating GFR using serum cystatin C alone and in combination
with serum creatinine: a pooled analysis of 3,418 individuals with
CKD</article-title><source>Am J Kidney Dis</source><year>2008</year><volume>51</volume><issue>3</issue><fpage>395</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">18295055</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalique</surname><given-names>O</given-names></name><name><surname>Aronow</surname><given-names>WS</given-names></name><name><surname>Ahn</surname><given-names>C</given-names></name><name><surname>Mazar</surname><given-names>M</given-names></name><name><surname>Schair</surname><given-names>B</given-names></name><name><surname>Shao</surname><given-names>J</given-names></name><etal/></person-group><article-title>Relation of moderate or severe reduction in glomerular filtration
rate to number of coronary arteries narrowed &#x0003e;50% in patients undergoing
coronary angiography for suspected coronary artery disease</article-title><source>Am J Cardiol</source><year>2007</year><volume>100</volume><issue>3</issue><fpage>415</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">17659920</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>GP</given-names></name><name><surname>Sukhova</surname><given-names>GK</given-names></name><name><surname>Grubb</surname><given-names>A</given-names></name><name><surname>Ducharme</surname><given-names>A</given-names></name><name><surname>Rhode</surname><given-names>LH</given-names></name><name><surname>Lee</surname><given-names>RT</given-names></name><etal/></person-group><article-title>Cystatin C deficiency in human atherosclerosis and aortic
aneurysms</article-title><source>J Clin Invest</source><year>1999</year><volume>104</volume><issue>9</issue><fpage>1191</fpage><lpage>1197</lpage><pub-id pub-id-type="pmid">10545518</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>Y</given-names></name></person-group><article-title>Correlation between serum cystatin C level and elderly
hypertensive patients combined coronary heart disease</article-title><source>Int J Clin Exp Med</source><year>2015</year><volume>8</volume><issue>4</issue><fpage>6287</fpage><lpage>6290</lpage><pub-id pub-id-type="pmid">26131241</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dandana</surname><given-names>A</given-names></name><name><surname>Gammoudi</surname><given-names>I</given-names></name><name><surname>Chalghoum</surname><given-names>A</given-names></name><name><surname>Chahed</surname><given-names>H</given-names></name><name><surname>Addad</surname><given-names>F</given-names></name><name><surname>Ferchichi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Clinical utility of serum cystatin C in predicting coronary
artery disease in patients without chronic kidney disease</article-title><source>J Clin Lab Anal</source><year>2014</year><volume>28</volume><issue>3</issue><fpage>191</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">24478035</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Sensitive and rapid quantification of C-reactive protein using
quantum dot-labeled microplate immunoassay</article-title><source>J Transl Med</source><year>2012</year><volume>10</volume><fpage>24</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">22309411</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>CL</given-names></name><name><surname>Ji</surname><given-names>YR</given-names></name><name><surname>Liu</surname><given-names>XH</given-names></name><name><surname>Xing</surname><given-names>JP</given-names></name><name><surname>Zhao</surname><given-names>JQ</given-names></name></person-group><article-title>Relationship between coronary atherosclerosis plaque
characteristics and high sensitivity C-reactive proteins,
interleukin-6</article-title><source>Chin Med J (Engl)</source><year>2011</year><volume>124</volume><issue>16</issue><fpage>2452</fpage><lpage>2456</lpage><pub-id pub-id-type="pmid">21933586</pub-id></element-citation></ref></ref-list></back></article>